PubMed Health⌕ Search

Biomedical subjects

S B Patten

Publications and source records attributed to S B Patten.

At least 19 recordsLinked to original sources

Modelling major depression epidemiology and assessing the impact of antidepressants on population health.

Randomized controlled trials indicate that antidepressant treatment increases the probability of remission in acute treatment of major depression, diminishes the frequency of relapse during continuation phase treatment and diminishes the risk of recurrence during maintenance treatment. As antidepressant coverage increases in the population, the benefits of antidepressant treatment should begin to translate into improved population health. However, adverse effects can also occur, as can unnecessary treatment. Monitoring the impact of antidepressant treatment on population health should be a priority for health surveillance. Quantitative description of the relationship between treatment provision and population health status will require the use of epidemiological models. A variety of such models have been reported in the literature. None of the existing models, however, are fully satisfactory.

Antidepressive Agents↗

Epidemic theory and group violence.

BACKGROUND: Epidemics can be represented mathematically using a variety of models. One of these, the Kermack-McKendrick model, has been used to support health policy decisions concerning vaccination requirements. An unrelated body of literature suggests that some behaviours, including some types of violence, may spread in ways analogous to the contagious spread of infectious diseases, a process that has been characterized as "behavioural contagion". METHOD: Various parameter values reflecting the characteristics of crowds were substituted into the Kermack-McKendrick model. Computer simulations were used to evaluate the impact of these parameter values. RESULTS: The simulations reproduced several features of crowd violence: the tendency for riots to occur in large groups, the importance of rapid removal of violent individuals from crowds, and the roles of alcohol consumption and social identification processes. CONCLUSIONS: Epidemic models may be of relevance to the prevention and control of violent behaviour as they can assist with the identification of high-risk situations and prevention strategies. Theoretical constructs related to epidemic theory may have broad applicability for modelling the unstable course of some mental disorders.

Disease Outbreaks↗

Off-label and non-classical prescriptions of antipsychotic agents in ordinary in-patient practice.

OBJECTIVE: To estimate the proportion of off-label prescriptions of antipsychotics (APs) in ordinary in-patient practice. METHOD: From the South-Verona Psychiatric Case Register all admissions to the in-patient unit during 2001-02 were extracted. Prescriptions of APs were defined off-label when dispensed outside the licensed indications. In addition, the proportion of "non-classical prescriptions" was calculated. RESULTS: During the 2 years surveyed AP agents were prescribed in 311 cases. Nearly 50% of second-generation AP prescriptions were for an off-label indication. In contrast, <15% of first-generation AP prescriptions were for an off-label indication. About 30% of first- and second-generation agents were prescribed for a non-classical indication. CONCLUSION: Approved labels for second-generation AP agents cover a much narrower range of indications than any of the first-generation agents, and this explains the higher proportion of off-label prescriptions. In contrast, the everyday use of first- and second-generation APs cover a similar range of clinical indications.

Antipsychotic Agents↗

The effect of immunomodulatory treatment on multiple sclerosis fatigue.

OBJECTIVE: To assess the effects of glatiramer acetate and beta interferon on fatigue in multiple sclerosis. METHODS: Fatigue was measured at baseline and six months using the fatigue impact scale (FIS). Groups (glatiramer acetate and beta interferon) were evaluated for the proportion improved, using Fisher's exact test. Logistic regression analysis assessed the relation between treatment group and improvement and controlled for confounding variables. RESULTS: Six month paired FIS assessments were available for 218 patients (76% female). Ages ranged between 19 and 61 years, with 86% having relapsing-remitting disease. Glatiramer acetate was used by 61% and beta interferon by 39%. At baseline, total FIS and subscale scores were comparable in the two groups. More patients improved on glatiramer acetate than on beta interferon on total FIS (24.8% v 12.9%, p = 0.033; adjusted odds ratio = 2.36, 95% confidence interval 1.03 to 5.42), and on physical (28.6% v 14.1%, p = 0.013) and cognitive subscales (21.1% v 10.6%, p = 0.045). Logistic regression analysis confirmed the association between glatiramer acetate use and improved fatigue, after accounting for baseline group differences. CONCLUSIONS: The odds of reduced multiple sclerosis fatigue were around twice as great with glatiramer acetate treatment as with beta interferon. Confirmation of this result is required.

Adjuvants, Immunologic↗

Major depression in multiple sclerosis: a population-based perspective.

OBJECTIVE: To determine the prevalence of major depression in multiple sclerosis (MS) in a population-based sample controlling for nonspecific illness effects. METHODS: This study used data from a large-scale national survey conducted in Canada: the Canadian Community Health Survey (CCHS). The analysis included 115,071 CCHS subjects who were 18 years or older at the time of data collection. The CCHS interview obtained self-reported diagnoses of MS and employed a brief predictive interview for major depression: the Composite International Diagnostic Interview Short Form for Major Depression. The 12-month period prevalence of major depression was estimated in subjects with and without MS and with and without other long-term medical conditions. RESULTS: The prevalence of major depression was elevated in persons with MS relative to those without MS and those reporting other conditions. The association persisted after adjustment for age and sex (adjusted odds ratio = 2.3, 95% CI 1.6 to 3.3). Major depression prevalence in MS for those in the 18- to 45-year age range was high at 25.7% (95% CI 15.6 to 35.7). CONCLUSIONS: The prevalence of major depression in the population with MS is elevated. This elevation is not an artifact of selection bias and exceeds that associated with having one or more other long-term conditions.

Adolescent↗

Long-term medical conditions and major depression in a Canadian population study at waves 1 and 2.

BACKGROUND: Cross-sectional studies have reported that certain long-term medical conditions are associated with major depression. Here, these associations are explored using a longitudinal analysis. METHODS: Data from the first (1994/95) and second (1996/97) waves of the Canadian National Population Health Survey (NPHS) were utilized. The first wave of the NPHS utilized a probability sample of 17626 members of the Canadian population. Members of this cohort were recontacted by Statistics Canada 2 years later. The Composite International Diagnostic Interview Short Form for Major Depression was used to identify episodes of major depression in both waves of the survey. Subjects free of major depression in the year preceding the 1994/95 survey were selected for inclusion in this analysis. The incidence of new-onset episodes in subjects with and without reported long-term medical conditions was compared. RESULTS: Individuals suffering from one or more long-term medical conditions were found to be at increased risk of major depression. Migraine headaches, sinusitis and back problems were the conditions most strongly associated with major depression. Having a long-term medical condition approximately doubled the risk of major depression in this analysis. LIMITATIONS: The most important limitation of this study was its reliance on self report data about medical conditions. CONCLUSIONS: A large proportion of the general population in Canada suffers from long-term medical conditions. These individuals are at increased risk of major depression. This study suggests an important role for long-term medical conditions in the etiology of major depression.

Adolescent↗

Perceived work stress and major depression in the Canadian employed population, 20-49 years old.

Data from the Canadian National Population Health Survey (1994-1995) were used to evaluate the associations between work stress and major depression (N = 7,344). Major depression was evaluated using the World Health Organization's Composite International Diagnostic Interview- Short Form. Work stress was measured by a 12-item scale in 6 dimensions. Significant associations between work stress and major depression were found. Gender may alter the type of work stress that is most strongly associated with major depression: psychological demands for men and physical demands for women. Some forms of work stress were more strongly associated with major depression in smokers than in nonsmokers.

Adult↗

Delirium in psychiatric inpatients: a case-control study.

OBJECTIVE: To investigate the clinical and pharmacoepidemiological determinants of delirium in a psychiatric inpatient population. METHOD: A case-control study design was used. Potential cases and potential controls were identified using hospital discharge data. The clinical record of each subject was reviewed using a validated protocol to confirm case and control status. Subsequently, exposure data were recorded from clinical records. RESULTS: Subjects admitted to hospital with delirium tended to be older, to have pre-existing cognitive deficits, and to have diagnoses of substance use disorders. Subjects who developed delirium after their admission to hospital were older than control subjects, more likely to have a history of cognitive impairment, and were significantly more likely to be treated during the hospitalization with lithium or anticholinergic antiparkinsonian medications. Antipsychotic medication exposures were also associated with delirium, but only at standard or above-standard dosage levels. Antidepressant and sedative-hypnotic medications were not associated with delirium. CONCLUSIONS: These findings indicate that using conservative dosages of antipsychotic medications and minimizing the use of anticholinergic medications for parkinsonian symptoms may help to prevent delirium in psychiatric inpatients. Anticonvulsant mood stabilizers may convey less delirium risk than lithium. Antidepressant medications and sedative-hypnotics were not important determinants of delirium in this population.

Adult↗

A prospective study of sex-specific effects of major depression on alcohol consumption.

OBJECTIVE: To evaluate the impact of major depression on alcohol use in the Canadian general population. METHOD: This study was based on a 2-year follow-up of the Canadian National Population Health Survey (NPHS) longitudinal cohort. Subjects reporting various patterns of drinking, with and without major depression, were selected using the 1994-95 NPHS data. Data collected during a reevaluation of these subjects 2 years later were analyzed to determine whether having major depression at the 1994-95 interview predicted subsequent changes in drinking patterns. RESULTS: Subjects who were depressed in 1994-95 were generally not at higher risk of starting drinking or drinking more frequently than once a week. However, women who were depressed, especially those who were 19 years old or older, were at higher risk of having 5 or more drinks at least once monthly. CONCLUSION: These results confirm that mood disorders can impact on alcohol consumption in women. A component of the well-known association between alcohol consumption and major depression is due to "reverse" causal effects. Proper management of depression in women may contribute to the prevention of problem drinking.

Alcohol Drinking↗

"Diet pills" and major depression in the Canadian population.

OBJECTIVE: To evaluate epidemiological associations between self-reported diet pill consumption and major depressive episodes (MDEs), using data from a large-scale, cross-sectional survey of the Canadian population. METHODS: Data from the National Population Health Survey (NPHS) were used in this analysis. The NPHS interview included a brief version of the Composite International Diagnostic Interview (CIDI) depression section, known as the CIDI Short Form for Major Depression (CIDI-SFMD), as well as provision for self-reported medication use. RESULTS: Approximately 0.5% of the population reported the use of diet pills. Diet pill use was more common among women than among men. At the time of data collection (1996-1997), the most commonly used medication was fenfluramine (since withdrawn from the market because of cardiovascular toxicity). The use of these medications was strongly associated with MDE: the annual prevalence among persons reporting use was 17.1% (95% CI, 8.6 to 25.6), approximately 4 times the underlying population rate. CONCLUSIONS: Because the NPHS was a general health survey, and because self-reported exposure to these medications was relatively uncommon, the data did not permit a detailed multivariate analysis. These findings, however, indicate that depressive psychopathology is strongly associated with the use of appetite-suppressant medications.

Appetite Depressants↗

Alternative medicine use by individuals with major depression.

OBJECTIVE: To describe the use of alternative medicine (AM) by persons with major depression and to examine the factors associated with AM use among these individuals. METHODS: We used data from the 1994-1995 and 1996-1997 National Population Health Surveys. We selected subjects who had major depression according to the Composite International Diagnostic Interview Short Form for Major Depression (CIDI-SFMD). The prevalence of AM and conventional health service use by the subjects was calculated for each survey and was stratified by province. We employed logistic regression to examine the factors associated with AM use. RESULTS: There was a temporal trend toward increasing use of AM among persons with major depression. The prevalence of AM use among subjects with major depression was 7.8% in 1994-1995 and 12.9% in 1996-1997. Female sex, having more than 12 years' education, and having 1 or more long-term medical conditions were associated with an increased likelihood of using AM. The sex difference in AM use depended on subjects' age in 1996-1997. CONCLUSION: General practitioners, mental health specialists, and AM providers should be aware of their patients' use of both conventional medical services and AM because there may be interactions between conventional and alternative treatments. Communication and, if possible, cooperation may lead to improved outcomes in the management of depressive disorders.

Adolescent↗

Alcohol consumption and major depression: findings from a follow-up study.

OBJECTIVE: To investigate whether alcohol consumption predicts major depressive disorder episodes (MDEs) in the general population. METHOD: The respondents without depression (n = 12,290) in the longitudinal cohort of the Canadian National Population Health Survey (NPHS) were classified into cohorts based on any drinking, frequency of drinking, maximum number of drinks on a maximal drinking occasion, and average daily alcohol consumption, based on data collected in the 1994-1995 survey. Major depression frequency 2 years later, in 1996-1997, was evaluated and compared across drinking categories. RESULTS: The respondents who reported any drinking, drinking daily, having more than 5 drinks on a maximal drinking occasion, and having more than 1 drink daily on average, did not have an elevated risk of major depression. A trend in the data suggested that women who reported having more than 5 drinks on a maximal drinking occasion might be at a higher risk of major depression. No evidence of confounding or effect modification by demographic, psychological, and clinical variables was found. CONCLUSION: In a general population sample, alcohol consumption levels were not associated with major depression. Having more than 5 drinks on a maximal drinking occasion, however, may be associated with an increased risk of major depression among women. Extreme patterns of alcohol consumption, which tend to characterize clinical samples, are associated with depression. These patterns of drinking, however, are relatively uncommon in the general population, and the current analysis may have lacked power to detect these associations.

Adolescent↗

Interferon beta-1 a and depression in relapsing-remitting multiple sclerosis: an analysis of depression data from the PRISMS clinical trial.

Depression is a suspected side effect of multiple sclerosis (MS) treatment with interferon beta-1a. However, this has not been confirmed by rigorous studies. Several psychological symptom rating scales were completed during the PRISMS clinical trial of subcutaneous interferon beta-1a (Rebif) for relapsing-remitting MS. We conducted an analysis of these data in order to determine whether symptom elevations were associated with treatment. The PRISMS clinical trial included 560 subjects from 22 centres in nine countries. There were two active treatment arms (44 mcg x 3 and 22 mcg x 3 subcutaneously three times per week) and a placebo group. Two hundred and sixty-seven of these subjects were enrolled at English speaking study centres, where psychiatric symptom ratings were obtained at baseline, 6, 12, 18 and 24 months using the Center for Epidemiological Studies Depression Rating Scale (CES-D), the General Health Questionnaire (GHQ) and the Beck Hopelessness Scale (BHS). After randomization, the groups completing these scales were similar in terms of age, gender, EDSS, duration of illness and employment status. Median CES-D scores in the high dose, low dose and placebo groups at baseline were also similar: 8.0, 7.0 and 8.0, respectively. After 6 months of treatment the median change in CES-D score was zero in all three groups. The proportion of subjects exceeding the traditional CES-D cut-point for clinically significant depression (> 15) after 6 months of treatment was strongly associated with pre-treatment depression (RR 2.9, 95% C.I.: 1.8-4.7), but not with treatment group (chi-square=1.64, d.f.=2, P=0.44). The results were comparable at 12, 18 and 24 months and when ratings from the other scales were evaluated. This analysis confirms that depression is common in persons with MS: the incidence of CES-D depression in the first 6 months of follow-up was 15.6%. However, no evidence of increased depressive symptomatology was observed in association with interferon beta-1a (Rebif).

Adjuvants, Immunologic↗

Major depression: prevalence, treatment utilization and age in Canada.

OBJECTIVE: To determine the relationships between age, prevalence of major depression and antidepressant treatment in Canadian populations by using data from three health surveys. BACKGROUND: Major depression is an important disorder, and there is a concern that treatment for it may be underutilized. Age may have an impact on treatment use. METHODS: Two of the surveys incorporated into the present analysis were random digit dial telephone surveys, with sample sizes of 2542 subjects and 796 subjects, respectively. The third data source was the National Population Health Survey (n=73,402), which used some face to face and some telephone-based data collection methods. In each of these studies, major depression was evaluated using a short form version of the Composite International Diagnostic Interview for Major Depression. Diagnostic status was evaluated in relation to current use of antidepressant medications, age and other relevant factors. All analyses accounted for unequal selection probabilities and clustering inherent in the sampling procedures. RESULTS: The prevalence of major depression was consistently found to be highest in subjects under the age of 45 years. However, older subjects were more likely to report having depression diagnosed. Antidepressant treatment was found to be less frequent in young subjects, despite these subjects being in the group with the highest prevalence of depression. Younger respondents were less likely to see a physician about their depressive symptoms, and when they did they were less likely to be told that they had a depressive disorder. CONCLUSIONS: The data presented indicate that antidepressant medications tend to be used less frequently in younger than older age groups in Canada. Additional studies are needed to confirm optimal use rates in relation to age.

Adolescent↗

Exogenous corticosteroids and major depression in the general population.

OBJECTIVE: An existing literature suggests that corticosteroid exposures are associated with an elevated level of depressive symptoms in various clinical populations. The objective of this study was to evaluate this association in a general population sample. METHODS: Data from a large-scale Canadian health survey were used in this analysis. The survey sample included 73,402 subjects over the age of 12 from the general Canadian population. The survey interview included a short-form version of the Composite International Diagnostic Interview (CIDI) section evaluating major depressive episodes. All estimates were weighted to account for unequal selection probabilities, and variance estimates were calculated using methods accounting for the survey design. RESULTS: A statistically significant elevation in major depression prevalence was observed in corticosteroid-treated subjects. The estimated 12-month period prevalence of major depression was approximately three times as high in corticosteroid treated vs. non-treated subjects irrespective of age, gender and perceived health. CONCLUSIONS: In the general population, persons taking corticosteroids have a higher frequency of major depression than non-exposed subjects. Because this was an analysis of cross-sectional survey data, causal inference is not possible. However, the existence of an epidemiological association, in conjunction with information from the broader literature, suggests that corticosteroid exposure may be a determinant of depressive disorders in the general population.

Adrenal Cortex Hormones↗